CARNEXIV Drug Patent Profile

Which patents cover Carnexiv, and what generic alternatives are available?

Carnexiv is a drug marketed by Lundbeck Pharms Llc and is included in one NDA. There are seven patents protecting this drug.

This drug has eighty patent family members in twenty-one countries.

The generic ingredient in CARNEXIV is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Carnexiv

A generic version of CARNEXIV was approved as carbamazepine by TARO on October 3^rd, 1996.

Summary for CARNEXIV

International Patents:	80
US Patents:	7
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	131
Patent Applications:	3,352
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CARNEXIV
What excipients (inactive ingredients) are in CARNEXIV?	CARNEXIV excipients list
DailyMed Link:	CARNEXIV at DailyMed

US Patents and Regulatory Information for CARNEXIV

CARNEXIV is protected by nine US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lundbeck Pharms Llc	CARNEXIV	carbamazepine	SOLUTION;INTRAVENOUS	206030-001	Oct 7, 2016		DISCN	Yes	No	9,629,797
Lundbeck Pharms Llc	CARNEXIV	carbamazepine	SOLUTION;INTRAVENOUS	206030-001	Oct 7, 2016		DISCN	Yes	No	9,770,407		Y
Lundbeck Pharms Llc	CARNEXIV	carbamazepine	SOLUTION;INTRAVENOUS	206030-001	Oct 7, 2016		DISCN	Yes	No	9,493,582		Y

International Patents for CARNEXIV

See the table below for patents covering CARNEXIV around the world.

Country	Patent Number	Title	Estimated Expiration
China	113395958	基本上无10-溴-卡马西平的可注射卡马西平组合物 (INJECTABLE CARBAMAZEPINE COMPOSITION ESSENTIALLY FREE OF 10-BR-CARBAMAZEPINE)
World Intellectual Property Organization (WIPO)	2020157257
Australia	2009241858

Market Dynamics and Financial Trajectory for CARNEXIV

Last updated: February 19, 2026

What is CARNEXIV and What is its Market Position?

CARNEXIV (sodium citrate/citric acid injection) is a intravenous therapy primarily indicated for treating hypovolemia, extracellular fluid reduction, and volume depletion. It was developed by Baxalta (a part of Takeda Pharmaceutical Company since 2019) and approved by the U.S. Food and Drug Administration (FDA) in 2017.[1]

Currently, CARNEXIV holds a niche market within intravenous volume replacement fluids, competing mainly against traditional options like albumin, saline-based solutions, and other plasma volume expanders.

How Has the Market for Volume Replacement Fluids Evolved?

The global market for volume replacement solutions was valued at approximately USD 10 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 6.8% over the next five years, reaching USD 14 billion by 2027.[2]

Growth drivers include increased surgical procedures, rising incidence of trauma and dehydration, and expanding intensive care units (ICUs). However, proprietary drugs like CARNEXIV face incremental challenges from cost pressures and the availability of generics.

What Are the Key Market Dynamics Influencing CARNEXIV?

Clinical Adoption Trends

CARNEXIV's adoption hinges on clinical preferences for volume expanders. While saline solutions and albumin are widely used, CARNEXIV offers a synthetic alternative with potentially reduced allergic reactions and infection risks.[3] Nonetheless, its adoption remains cautious due to clinical familiarity with traditional therapies.

Pricing and Reimbursement Policies

Pricing strategies impact CARNEXIV’s market penetration. As a specialty intravenous solution, CARNEXIV’s per-dose cost exceeds that of saline—approximately USD 150-200 per vial versus USD 2-10 for saline.[4] Reimbursement policies from Medicare, Medicaid, and private insurers influence hospitals’ willingness to prescribe.

Regulatory Environment

Post-approval, CARNEXIV received FDA labeling for specific indications. Expanded approval for broader uses could stimulate demand. Conversely, regulatory restrictions or safety concerns could delay market growth.

Competitive Landscape

CARNEXIV faces competition from existing volume expanders:

Product	Type	Price per Dose	Approval Date
Normal saline	Crystalloid solution	USD 2-10	Established (pre-2000)
Albumin 5%/25%	Plasma protein expander	USD 30-100 per 50ml	Approved since 1959-1999
Hydroxyethyl starch	Synthetic colloid	USD 50-100 per 500ml	Approved since 1970s
CARNEXIV	Citrate-based synthetic volume expander	USD 150-200 per vial	FDA approval in 2017

While CARNEXIV offers theoretical advantages, clinical preference for established therapies constrains rapid uptake.

What Are Revenue Drivers and Challenges?

Revenue Drivers

• Increasing ICU admissions globally enhance demand for volume expanders.
• Growing surgical volumes, especially in emerging markets, expand potential customer base.
• Expanding indications through clinical studies could open new revenue streams.

Challenges

• Competition from less expensive, well-established solutions.
• High per-dose cost limits hospital and insurer acceptance.
• Slow physician adoption due to clinical inertia.
• Stringent regulatory pathways for indication expansion.

What Is the Financial Trajectory and Forecast?

CARNEXIV’s commercial performance remains modest. Limited sales data indicate annual revenue figures below USD 50 million since 2018, with some growth in North America and select European markets.

Based on current market size and adoption rates, projections estimate:

Year	Estimated Revenue	Market Penetration	Remarks
2023	USD 20 million	0.2%	Early-stage adoption, primarily in ICUs
2025	USD 50 million	0.5%	Growth driven by expanded clinical use
2027	USD 80 million	0.75%	Increased acceptance, some indication expansion

Market growth is limited by competition and reimbursement barriers but could accelerate if expanded labeling occurs or if cost-effective manufacturing reduces prices.

How Will Market and Financial Dynamics Evolve?

• Accelerated adoption depends on further evidence of clinical benefits.
• Price reductions could improve market penetration.
• Regulatory approvals for broader indications would drive higher revenues.
• Entering emerging markets could expand volume but require tailored pricing strategies.

Key Takeaways

• CARNEXIV operates in a niche intravenous volume expander segment with limited market share.
• Market growth aligns with broader trends in ICU admissions and surgical procedures.
• Price and clinical adoption pose significant hurdles.
• Revenue projections suggest slow but steady growth through 2027.
• Competitive landscape and reimbursement policies critically influence long-term success.

FAQs

1. What are the main competitors to CARNEXIV?
Normal saline, albumin solutions, and hydroxyethyl starch are the primary competitors. They are more established and generally less expensive.

2. How does CARNEXIV compare in price?
A typical vial costs USD 150-200, notably higher than saline, which costs USD 2-10 per administration.

3. Can expanding indications increase revenue?
Yes. Broader clinical approvals can expand usage, particularly if clinical benefits over traditional solutions are demonstrated.

4. What regulatory hurdles exist?
FDA approval for additional indications and evidence of safety and efficacy can extend approval timelines and impact market adoption.

5. Is emerging market expansion feasible?
Yes, but it requires strategic pricing and partnerships to address cost sensitivities and regulatory environments.

---

References

[1] FDA. (2017). FDA approves Baxalta’s CARNEXIV for IV volume replacement.
[2] MarketsandMarkets. (2022). Volume replacement solutions market report.
[3] Company disclosures. (2022). Clinical benefits of CARNEXIV.
[4] IMS Health. (2022). Drug price benchmarks.